Locus heterogeneity in progressive familial intrahepatic cholestasis

Sandra S Strautnieks, Amir F Kagalwalla, M Stuart Tanner, R Mark Gardiner, Richard J Thompson

Abstract

Progressive familial intrahepatic cholestasis (PFIC or Byler disease) is a rare autosomal recessive form of severe and fatal cholestatic liver disease. A locus for PFIC has recently been mapped to chromosome 18q21–q22 in the original Byler pedigree. This region harbours the locus for a related phenotype, benign recurrent intrahepatic cholestasis (BRIC), suggesting that these traits are allelic. Linkage analysis was undertaken in five consanguineous PFIC pedigrees from Saudi Arabia using marker loci (D18S69, D18S41, D18S64, D18S38, D18S42, D18S55, D18S68, and D18S61) which span the Byler disease/BRIC region on 18q21–q22. In this family set the disease locus was excluded from this region, showing that locus heterogeneity exists for the PFIC phenotype.

Key words: liver; cholestasis; familial; heterogeneity.

There are a number of separate identifiable cholestatic diseases with onset in childhood, some of which have obvious mendelian inheritance. Some are clearly syndromic, with non-hepatic manifestations, such as Alagille and Ajaenaeae syndromes. Others have characteristic histological or biochemical features. Progressive familial intrahepatic cholestasis (PFIC or Byler disease, OMIM 211600) is an example of the latter. PFIC was first described in a large Amish pedigree and patients with the same disease phenotype have now been described in many populations. Inheritance is autosomal recessive with a high incidence of parental consanguinity. Despite the fact that the term PFIC has been applied to a variety of familial cholestatic phenotypes, the patients used in this research and the discussion thereof are restricted to the phenotype corresponding to that seen in the original Byler family. The disease presents in the first few months of life with intense pruritis, jaundice, malabsorption, loose stools, and failure to thrive. A number of characteristic features distinguish PFIC from other cholestatic diseases. Initially there appears to be a relapsing course, with clearing of jaundice between episodes, but progression occurs to severe persistent cholestasis and biliary cirrhosis. The episodic jaundice is associated with a marked rise of serum bile acids and depression of biliary bile acids and these changes become persistent. The most unusual and striking feature of these children is that neither the serum cholesterol nor the y-glutamyl transpeptidase (yGT) are raised.

These findings in particular differentiate PFIC from other cholestatic diseases, as bile is the only route of cholesterol excretion, and yGT is released from the biliary epithelium by any damage, particularly by bile acids. Liver biopsy shows marked intrahepatic cholestasis with progressive fibrosis. Death usually occurs in the first or early in the second decade of life.

Benign recurrent intrahepatic cholestasis (BRIC, OMIM 243300) is a similar but phenotypically quite distinct condition. BRIC patients also have intermittent cholestasis and jaundice but remain otherwise well and there is no progression to chronic liver disease. A BRIC locus has been mapped to chromosome 18q21–22 in an isolated Dutch population with a presumed founder mutation. Subsequently, in members of the original Byler family, a locus for PFIC has been mapped to the same chromosomal region. It is assumed that the causative gene will be involved in bile acid transport within the liver, but no plausible candidate genes have yet been identified in this region of chromosome 18.

Linkage analysis was undertaken in five unrelated consanguineous Saudi Arabian families segregating PFIC, using marker loci spanning the region of chromosome 18 to which BRIC and PFIC have been mapped. No regions of homozygosity were seen in any of the affected people, and negative lod scores across the region were obtained in all families. This provides unequivocal evidence for locus heterogeneity in PFIC.

Materials and methods

SUBJECTS

Six affected children from five first cousin marriages, their parents, and a total of 12 unaffected sibs were analysed (fig 1). Six further children from family 4 are known to have already died from severe cholestatic liver disease. The five families are not known to be related. The affected subjects all have jaundice with onset in the first three months of life, pruritis with maximum age of onset of 7 months, and severe failure to thrive. All the affected children have biochemical and histological evidence of marked cholestasis, with very raised serum bile acid concentrations, low or normal cholesterol levels, and normal yGT levels (table 1). They all have liver biopsy appearances of severe intrahepatic cholestasis and cirrhosis.
Table 1  Clinical data of the patients in this study. These are the most recent available for each patient. The normal ranges of the laboratory in which the estimations were made are given.

<table>
<thead>
<tr>
<th>Family</th>
<th>Patient</th>
<th>Age at presentation (y)</th>
<th>Current age (y)</th>
<th>Bilirubin (NR 0-22 μmol/l)</th>
<th>Aspartate transaminase (NR 11-55 IU/l)</th>
<th>γ-Glutamyl transpeptidase (NR 5-37 IU/l)</th>
<th>Alkaline phosphatase (NR 100-280 IU/l)</th>
<th>Cholesterol (NR 2.3-6.9 mmol/l)</th>
<th>Bile acids (NR 0-8.9 μmol/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>II.2</td>
<td>0.2</td>
<td>5</td>
<td>171</td>
<td>291</td>
<td>36</td>
<td>760</td>
<td>1.3</td>
<td>256</td>
</tr>
<tr>
<td>2</td>
<td>II.3</td>
<td>0.25</td>
<td>2</td>
<td>335</td>
<td>259</td>
<td>16</td>
<td>794</td>
<td>3.77</td>
<td>131</td>
</tr>
<tr>
<td>3</td>
<td>II.1</td>
<td>0.1</td>
<td>11</td>
<td>20</td>
<td>151</td>
<td>19</td>
<td>1877</td>
<td>5.48</td>
<td>291</td>
</tr>
<tr>
<td>4</td>
<td>II.2</td>
<td>0.5</td>
<td>1.5</td>
<td>247</td>
<td>1352</td>
<td>43</td>
<td>746</td>
<td>4.9</td>
<td>123</td>
</tr>
<tr>
<td>5</td>
<td>II.3</td>
<td>0.75</td>
<td>9</td>
<td>101</td>
<td>119</td>
<td>28</td>
<td>471</td>
<td>5.5</td>
<td>237</td>
</tr>
</tbody>
</table>

NR = normal range.

Figure 1  Pedigrees of the PFIC families used in this study. All marriages are between first cousins. Sibs unavailable for genotyping are not shown. The allele data at the marker loci is shown beneath each subject. The numbers are allele sizes and are based on PCR product sizes measured in mobility units. Genotypes unavailable are given as (-----).

Figure 2  Sizes measured in mobility units from the PCR products for 21 loci on chromosome 18 are shown.
Locus heterogeneity in progressive familial intrahepatic cholestasis

Figure 2. Multipoint analysis of PFIC region of chromosome 18q21-22. Horizontal scale marked in 1 cM intervals. Vertical scale shows location lod score. The PFIC locus previously described is shown above the axis, as defined by limiting recombinants.7 The sex averaged distances in cM between loci are D18S69-2-D18S41-5-D18S64-3-D18S38-7.5-D18S42-1-D18S55-1-D18S68-9-D18S61.

MARKER TYPING
Genomic DNA was extracted from white cells by standard methods. DNA was amplified by the polymerase chain reaction (PCR) using fluorescently labelled primers. The markers used were D18S69, D18S41, D18S64, D18S38, D18S42, D18S55, D18S68, and D18S61. Primer sequence and allele frequency data for these markers are available from the Genome Database (GDB). PCR was performed in 96 well microtitre plates (Hybaid). Each well contained 20–50 ng of genomic DNA; 1.5 mmol/l MgCl₂; 1 × reaction buffer (Advanced Biotechnologies, UK); 200 mmol/l each of dGTP, dATP, dTTP, and dCTP; 50 ng of each primer; and 0.2 U of Red Hot DNA polymerase (Advanced Biotechnologies, UK), in a total volume of 15 µl. Thirty cycles were performed in a thermocycler (Hybaid Omnigene™). Alkaline was separated through a 6% polyacrylamide electrophoresis gel for three to four hours at a rate limiting voltage of 1000 volts using a model 373A DNA sequencer (Applied Biosystems). Analysis of the allele sizes was carried out by GENESCAN™672 (version 1.2) and Genotyper softwares (Applied Biosystems) using GENESCAN™500 TAMRA.

RESULTS
No significant common regions of homozygosity were identified (fig 1). At all the marker loci examined, with the exception of D18S42, at least one person was homozygous. In seven of the 11 such loci the parents were also homozygous, rendering the corresponding meioses uninformative. Both children in family 5 were homozygous at D18S64 as was one parent. In family 5, the homozygosity seen at D18S68 and D18S61 is not common to both patients indicating obligate recombinants.

The statistical significance of these results can be represented as a multipoint lod score. The individual family multipoint lod scores were consistently negative over the whole region examined, though as each family is small no one family achieved a region of exclusion (defined as a lod score of less than -2) of more than a few centimorgans. However, the maximum total lod score assuming locus homogygosity was -4.3 over the genetic interval defined by D18S69 and D18S61 (fig 2). The unlikely possibility that each family has acquired a second disease allele by marriage can be allowed for by increasing the disease allele frequency to 0.10. Under this model the maximum lod score over this region is -2.9.

DISCUSSION
The absence of homozygosity in a set of closely linked markers has entirely excluded the PFIC/BRIC locus on chromosome 18 in these families, assuming inheritance of two copies of a disease gene from a great grandparent. The only other mechanism which needs to be considered is that all the families have acquired a disease allele by marriage to an unrelated person. Even this possibility can be excluded by...
the observation of obligate recombinants within the region.

The patients used in this study are phenotypically indistinguishable from the affected subjects in the Byler family. Although the mapping of the PFIC locus involved only two affected subjects, a large number of ancestral meioses were examined in the analysis. Therefore the likelihood of the observed common segments being inherited by chance, and therefore not containing the disease gene, was 1 in $1 \times 10^5$. We have excluded this region of 18q in our families. These new data therefore show locus heterogeneity.

The biochemical features of PFIC suggest a defect in the transport of bile acids from blood to bile. Bile acids are synthesised by hepatocytes and are actively excreted in bile. Ninety percent of the bile acid content of bile is reabsorbed in the small intestine and enters the portal circulation. In normal people uptake of bile acids by hepatocytes achieves a first pass clearance of 80–90%. Under normal circumstances they are therefore subject to an efficient entero-hepatic circulation. As a result total serum bile acids are normally maintained at less than 10 $\mu$mol/l in peripheral blood. To achieve this there are highly efficient bile acid uptake mechanisms on the basolateral surface of hepatocytes. It is assumed that cytoskeletal elements are involved in transcytotic movement of bile acids, and that there are multiple, quite distinct, transporters on the canalicular surface. There are a number of anatomical sites at which bile acid transport could fail: basolateral membrane, intracellular transporters, or at the canalicular membrane. The severity of the liver disease in PFIC suggests an intracellular accumulation of bile acids. In contrast, a failure of uptake at the basolateral membrane would be unlikely to lead to severe hepatitis and cirrhosis, making this an implausible site for the causative defects in PFIC. Therefore, the luminal membrane or the cytoskeleton would seem to be the most likely candidates for the site of the defect. Electronmicroscopy of PFIC liver biopsies shows pericentral microfilamentous condensation, as seen in phalloidin administration, suggesting that the abnormalities of the cytoskeleton may underlie PFIC. However, similar changes have been noted in extrahepatic biliary obstruction. This may therefore be a secondary effect.

There is evidence in some BRIC families of a phenotype associated with the carrier state. Mothers of children with BRIC, themselves obligate heterozygotes, appear to have an increased incidence of cholestasis of pregnancy. This suggests that the defect in BRIC/PFIC is in a mechanism in which there is an excess functional capacity in normal people and in which heterozygotes have adequate capacity and therefore a normal phenotype until stressed. These new data indicate that there are at least two genes capable of causing phenotypically indistinguishable critical disruption of bile acid transport, probably at the same cellular site.

Cloning of the genes which cause PFIC will greatly increase our understanding of normal bile acid transport mechanisms in the liver. Furthermore, although it appears that the two distinct phenotypes of PFIC and BRIC are allelic, PFIC itself exhibits locus heterogeneity. This is not, of course, the first instance in which linkage studies have shown that apparently distinct phenotypes represent an allelic series or that an apparently homogeneous phenotype encompasses locus heterogeneity. Recent studies of the fibroblast growth factor receptor (FGFR) genes in the craniofacial dysmorphology syndromes Crouzon disease (arising from mutations in FGFR2) and Pfeiffer syndrome (an allelic variant at FGFR2) but also caused by mutations in FGFR1 are good examples. Once again our understanding of genetics will require and allow us to redefine clinical syndromes.

We are very grateful for the cooperation of the patients and their families. RT is a Wellcome Trust Medical Graduate Research Training Fellow.

Locus heterogeneity in progressive familial intrahepatic cholestasis.

S S Strautnieks, A F Kagalwalla, M S Tanner, R M Gardiner and R J Thompson

*J Med Genet* 1996 33: 833-836
doi: 10.1136/jmg.33.10.833

Updated information and services can be found at:
http://jmg.bmj.com/content/33/10/833

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/